Goodwin Procter

Goodwin Procter is a global law firm headquartered in Boston, MA, with over 1,800 attorneys across 17 offices in North America, Europe, and Asia. Consistently ranked among the largest firms by revenue, Goodwin is recognized as a top-tier AmLaw firm, most recently ranking 18th or 19th on The American Lawyer's annual list by gross revenue. The firm operates on a "capital-meets-innovation platform," advising clients in high-growth sectors such as life sciences, technology, and financial services.

Goodwin's Intellectual Property Litigation practice is known for its expertise across a broad range of technology areas, notably in life sciences (including Hatch-Waxman, biologics, and biosimilars litigation) and high-stakes technology disputes (such as semiconductors, digital rights management, and signal processing). The firm represents national and international companies, with more than 80 dedicated IP litigators, over 60 of whom hold technical degrees. Goodwin regularly handles matters for both plaintiffs (8 tracked cases) and defendants (6 tracked cases), demonstrating a balanced approach in its litigation strategy, including representing both innovator and biosimilar companies in complex disputes.

Notable engagements include securing a $308.5 million jury verdict for Personalized Media Communications (PMC) against Apple Inc. in a patent infringement case related to digital rights management technology. While a subsequent district court ruling found the patent unenforceable based on prosecution laches, which was affirmed by the Federal Circuit, the initial jury victory underscored the firm's trial capabilities. The firm also represented Regeneron Pharmaceuticals Inc. in its BPCIA case against Mylan Pharmaceuticals Inc., resulting in a December 2023 judgment finding certain patent claims valid and infringed, and an injunction granted in favor of Regeneron. Appeals in that case were dismissed for lack of jurisdiction in April 2024. Additionally, Goodwin represented Alvotech as plaintiff in Alvotech v. Regeneron Pharmaceuticals, Inc., which saw a December 2025 settlement allowing Alvotech and Teva to launch a biosimilar in late 2026.

The firm possesses significant experience before the Patent Trial and Appeal Board (PTAB), having served as lead counsel in hundreds of PTAB matters. Key partners in Goodwin's Intellectual Property Litigation practice include Elaine Herrmann Blais and Brett M. Schuman, who serve as Co-Chairs of the practice, alongside other prominent litigators such as Douglas J. Kline and Lori A. Gordon.